Identity
- Security key
- 14322
- Ticker
- DMRA
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2020-10-29
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- DMRA
Detail
Enriched 2026-08-14 20:47
- Market cap
- $1,913,801,089
- Shares outstanding (class)
- —
- Shares outstanding (weighted)
- 61,735,519
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 7
- Location
- WALTHAM, MA
- Homepage
- https://www.damoratx.com
- Description
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Market cap and share counts drift.